Eurofins Responds to Increased Demand for COVID-19 Testing at Schools With Cost-effective Testing Programmes for the Educational Sector
19 Octobre 2021 - 5:45PM
Business Wire
Eurofins (Paris:ERF):
Easy, reliable, high quality and cost-effective testing for
SARS-CoV-2 (COVID-19) is critical to help reopen and keep open many
aspects of society and business sectors worldwide. Eurofins is
working with schools and education authorities to design and
implement cost-effective solutions to test this important part of
our community regularly and reliably.
Since spring 2021, Eurofins has been supporting schools in
Europe and the USA through COVID-19 monitoring programmes, in
collaboration with local health and education authorities. Group
companies pioneered case studies, early in the pandemic, in schools
in the USA and Germany to assess the effectiveness of pooled PCR
testing. The findings of these studies have allowed Eurofins to
develop customer-focussed, cost-effective testing solutions for
schools and universities. Pooled testing is underpinned by the gold
standard of COVID-19 PCR testing, but significantly reduces the
cost of monitoring programmes by simultaneously testing a group, or
‘pool’, of samples to detect the presence of SARS-CoV-2. Such
pooled testing programmes can be replicated in other settings, such
as care facilities and workplaces.
These school monitoring programmes are effective and easy to
carry out and have been proven to:
- Quickly identify positive cases from
symptomatic and asymptomatic individuals to enable rapid isolation
and contact tracing. - Increase confidence in in-person teaching
among school staff and parents. - Distinguish between seasonal flu
and COVID-19 infections and avoid unnecessary isolation
measures.
Having ramped up the necessary capacity, Eurofins intends to
continue to support communities around the world with innovative
and cost-effective COVID-19 testing solutions and expand its
partnerships within the education sector to facilitate schooling in
safe environments.
Since 2020, Eurofins has reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and services and has carried out over 30
million PCR tests in its own laboratories.
For more information, please visit SAFER@WORKTM
Notes for the editor:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network
of 900 laboratories in over 50 countries, Eurofins’ companies offer
a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005923/en/
Investor Relations Eurofins Scientific SE Gabriel JULIA E-mail:
ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024